New drug targets tough KRAS cancers in early trial
NCT ID NCT07204340
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This early-phase study tests a new drug called TLN-372 in people with advanced solid tumors that have a KRAS mutation. The goal is to check the drug's safety and how well it works, both alone and with other cancer treatments. About 240 adults with measurable, advanced or metastatic tumors will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS MUTANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215-5450, United States
Contact Email: •••••@•••••
-
Hospital Universitary Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
Linear Clinical Research
RECRUITINGPerth, Western Australia, 6009, Australia
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10021-3402, United States
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Victoria, Australia
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 1X6, Canada
-
START Madrid_Hospital Universitario HM Sanchinarro_CIOCC
RECRUITINGMadrid, 28050, Spain
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
-
Washington University Medical Campus
RECRUITINGSt Louis, Missouri, 63108, United States